GB0121033D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0121033D0
GB0121033D0 GBGB0121033.5A GB0121033A GB0121033D0 GB 0121033 D0 GB0121033 D0 GB 0121033D0 GB 0121033 A GB0121033 A GB 0121033A GB 0121033 D0 GB0121033 D0 GB 0121033D0
Authority
GB
United Kingdom
Prior art keywords
cathepsin
organic compounds
osteoarthritis
osteoporosis
implicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0121033.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0121033.5A priority Critical patent/GB0121033D0/en
Publication of GB0121033D0 publication Critical patent/GB0121033D0/en
Priority to MYPI20023181A priority patent/MY157368A/en
Priority to ARP020103229A priority patent/AR036374A1/es
Priority to TW091119570A priority patent/TWI297690B/zh
Priority to KR1020047003048A priority patent/KR100695845B1/ko
Priority to BR0212226-0A priority patent/BR0212226A/pt
Priority to DE60211530T priority patent/DE60211530T2/de
Priority to RU2004109815/04A priority patent/RU2331644C2/ru
Priority to JP2003524991A priority patent/JP4629334B2/ja
Priority to ES02797553T priority patent/ES2262888T3/es
Priority to NZ531343A priority patent/NZ531343A/en
Priority to US10/487,760 priority patent/US7452886B2/en
Priority to AT02797553T priority patent/ATE326469T1/de
Priority to AU2002333760A priority patent/AU2002333760B2/en
Priority to PL02368280A priority patent/PL368280A1/xx
Priority to HK05104226.3A priority patent/HK1072254B/xx
Priority to IL16036702A priority patent/IL160367A0/xx
Priority to CA002458684A priority patent/CA2458684C/en
Priority to SI200230374T priority patent/SI1423391T1/sl
Priority to CNB028168402A priority patent/CN100372849C/zh
Priority to EP02797553A priority patent/EP1423391B8/en
Priority to HU0401301A priority patent/HUP0401301A3/hu
Priority to MXPA04001935A priority patent/MXPA04001935A/es
Priority to PE2002000833A priority patent/PE20030418A1/es
Priority to PCT/EP2002/009663 priority patent/WO2003020721A1/en
Priority to DK02797553T priority patent/DK1423391T3/da
Priority to PT02797553T priority patent/PT1423391E/pt
Priority to ZA200401042A priority patent/ZA200401042B/en
Priority to IL160367A priority patent/IL160367A/en
Priority to EC2004004998A priority patent/ECSP044998A/es
Priority to NO20041180A priority patent/NO328890B1/no
Priority to CY20061101095T priority patent/CY1105573T1/el
Priority to US12/237,896 priority patent/US20090054467A1/en
Priority to IL198643A priority patent/IL198643A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0121033.5A 2001-08-30 2001-08-30 Organic compounds Ceased GB0121033D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds
MYPI20023181A MY157368A (en) 2001-08-30 2002-08-27 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
ARP020103229A AR036374A1 (es) 2001-08-30 2002-08-28 Pirrolo pirimidinas.
TW091119570A TWI297690B (en) 2001-08-30 2002-08-28 Pyrrolo pyrimidines,pharmaceutical composition for treating a patient suffering from or susceptible to a disease or medical condition in which cathepsin k is implicated comprising the same,and process for the preparation thereof
PT02797553T PT1423391E (pt) 2001-08-30 2002-08-29 Pirrolopirimidinas como agentes para a inibicao de proteases de cisteina
IL16036702A IL160367A0 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
CNB028168402A CN100372849C (zh) 2001-08-30 2002-08-29 作为半胱氨酸蛋白酶抑制剂的吡咯并嘧啶化合物
DE60211530T DE60211530T2 (de) 2001-08-30 2002-08-29 Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen
RU2004109815/04A RU2331644C2 (ru) 2001-08-30 2002-08-29 Пирролопиримидины, обладающие свойствами ингибитора катепсина к, и способ их получения (варианты)
JP2003524991A JP4629334B2 (ja) 2001-08-30 2002-08-29 システインプロテアーゼの阻害因子としてのピロロピリミジン
ES02797553T ES2262888T3 (es) 2001-08-30 2002-08-29 Pirrolopirimidinas como agentes para la inhibicion de proteasas de cisteina.
NZ531343A NZ531343A (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
US10/487,760 US7452886B2 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
AT02797553T ATE326469T1 (de) 2001-08-30 2002-08-29 Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen
AU2002333760A AU2002333760B2 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
PL02368280A PL368280A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
HK05104226.3A HK1072254B (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
KR1020047003048A KR100695845B1 (ko) 2001-08-30 2002-08-29 시스테인 프로테아제 억제제로서의 피롤로 피리미딘
CA002458684A CA2458684C (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
SI200230374T SI1423391T1 (sl) 2001-08-30 2002-08-29 Pirolo pirimidini kot sredstva, ki inhibirajo cisteinske proteaze
BR0212226-0A BR0212226A (pt) 2001-08-30 2002-08-29 Pirrolo pirimidinas como agentes para inibição de cisteìna proteases
EP02797553A EP1423391B8 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
HU0401301A HUP0401301A3 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them
MXPA04001935A MXPA04001935A (es) 2001-08-30 2002-08-29 Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina.
PE2002000833A PE20030418A1 (es) 2001-08-30 2002-08-29 Pirrolo pirimidinas como inhibidores de cisteina proteasas
PCT/EP2002/009663 WO2003020721A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
DK02797553T DK1423391T3 (da) 2001-08-30 2002-08-29 Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser
ZA200401042A ZA200401042B (en) 2001-08-30 2004-02-09 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases.
IL160367A IL160367A (en) 2001-08-30 2004-02-12 Pyrrolo pyrimidines as agents for the inhibition of cysteine proteases
EC2004004998A ECSP044998A (es) 2001-08-30 2004-03-01 Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina
NO20041180A NO328890B1 (no) 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse
CY20061101095T CY1105573T1 (el) 2001-08-30 2006-08-03 Πυρρολο πυριμιδινες ως ανασταλτικοι παραγοντες των πρωτεασων κυστεϊνης
US12/237,896 US20090054467A1 (en) 2001-08-30 2008-09-25 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases
IL198643A IL198643A (en) 2001-08-30 2009-05-07 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
GB0121033D0 true GB0121033D0 (en) 2001-10-24

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0121033.5A Ceased GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds

Country Status (29)

Country Link
US (2) US7452886B2 (enExample)
EP (1) EP1423391B8 (enExample)
JP (1) JP4629334B2 (enExample)
KR (1) KR100695845B1 (enExample)
CN (1) CN100372849C (enExample)
AR (1) AR036374A1 (enExample)
AT (1) ATE326469T1 (enExample)
AU (1) AU2002333760B2 (enExample)
BR (1) BR0212226A (enExample)
CA (1) CA2458684C (enExample)
CY (1) CY1105573T1 (enExample)
DE (1) DE60211530T2 (enExample)
DK (1) DK1423391T3 (enExample)
EC (1) ECSP044998A (enExample)
ES (1) ES2262888T3 (enExample)
GB (1) GB0121033D0 (enExample)
HU (1) HUP0401301A3 (enExample)
IL (3) IL160367A0 (enExample)
MX (1) MXPA04001935A (enExample)
MY (1) MY157368A (enExample)
NO (1) NO328890B1 (enExample)
NZ (1) NZ531343A (enExample)
PE (1) PE20030418A1 (enExample)
PL (1) PL368280A1 (enExample)
PT (1) PT1423391E (enExample)
RU (1) RU2331644C2 (enExample)
TW (1) TWI297690B (enExample)
WO (1) WO2003020721A1 (enExample)
ZA (1) ZA200401042B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
CN102526079B (zh) 2002-09-24 2014-06-18 诺华股份有限公司 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
JP4710606B2 (ja) * 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
MXPA05011593A (es) * 2003-04-28 2005-12-15 Novartis Ag Composicion farmaceutica que comprende un inhibidor de catepsina s y un opioide.
JP2006525336A (ja) * 2003-04-30 2006-11-09 エフ　エム　シー　コーポレーション フェニル置換した環状誘導体
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1786816A4 (en) * 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
BRPI0507498A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
WO2005111042A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
AU2006277678B2 (en) * 2005-08-05 2012-04-19 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
EP1933860A2 (en) 2005-09-01 2008-06-25 Ares Trading S.A. Treatment of optic neuritis
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
WO2007067504A2 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200934771A (en) 2007-10-19 2009-08-16 Astrazeneca Ab New compounds
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CN102482278B (zh) 2009-06-29 2015-04-22 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2519525A4 (en) 2009-12-30 2013-06-12 Arqule Inc SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS
US9115126B2 (en) 2010-01-15 2015-08-25 Merck Sharp & Dohme B.V. 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
AU2011311452B2 (en) 2010-10-06 2016-09-01 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
TWI648277B (zh) 2011-09-02 2019-01-21 美商英塞特控股公司 作為ｐｉ３ｋ抑制劑之雜環基胺
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN104284895B (zh) * 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
CA2875918A1 (en) 2012-06-06 2013-12-12 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
HK1213946A1 (zh) 2012-10-12 2016-07-15 Inbiomotion S.L. 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
ES2727904T3 (es) 2013-10-09 2019-10-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
CA3285092A1 (en) 2015-02-27 2025-11-29 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2017203468A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CN120053645A (zh) 2018-06-01 2025-05-30 因赛特公司 治疗pi3k相关病症的给药方案
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) * 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
KR20240090633A (ko) * 2021-12-01 2024-06-21 에스티팜 주식회사 트리아졸로피리미디논 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) * 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
ATE247469T1 (de) * 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
ES2202827T3 (es) * 1997-03-19 2004-04-01 ABBOTT GMBH & CO. KG Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa.
DE69934311D1 (de) * 1998-06-30 2007-01-18 Lilly Co Eli BICYCLISCHE sPLA 2-INHIBITOREN
PL346700A1 (en) * 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
GEP20053479B (en) * 1999-12-10 2005-03-25 Pfizer Prod Inc Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
CA2402516A1 (en) * 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物

Also Published As

Publication number Publication date
RU2004109815A (ru) 2005-10-20
HK1072254A1 (zh) 2005-08-19
BR0212226A (pt) 2004-08-17
WO2003020721A1 (en) 2003-03-13
HUP0401301A3 (en) 2008-03-28
CN100372849C (zh) 2008-03-05
CN1549817A (zh) 2004-11-24
CY1105573T1 (el) 2010-07-28
IL198643A (en) 2010-12-30
MY157368A (en) 2016-06-15
EP1423391A1 (en) 2004-06-02
PE20030418A1 (es) 2003-06-12
ZA200401042B (en) 2004-10-25
JP4629334B2 (ja) 2011-02-09
CA2458684C (en) 2009-04-07
IL160367A (en) 2009-12-24
ECSP044998A (es) 2004-04-28
DE60211530T2 (de) 2006-12-21
EP1423391B1 (en) 2006-05-17
US20090054467A1 (en) 2009-02-26
TWI297690B (en) 2008-06-11
NZ531343A (en) 2006-01-27
ATE326469T1 (de) 2006-06-15
MXPA04001935A (es) 2004-06-15
ES2262888T3 (es) 2006-12-01
IL160367A0 (en) 2004-07-25
RU2331644C2 (ru) 2008-08-20
KR100695845B1 (ko) 2007-03-20
HUP0401301A2 (hu) 2004-10-28
AR036374A1 (es) 2004-09-01
DK1423391T3 (da) 2006-09-25
NO328890B1 (no) 2010-06-07
PL368280A1 (en) 2005-03-21
EP1423391B8 (en) 2007-12-12
US20050054851A1 (en) 2005-03-10
AU2002333760B2 (en) 2007-01-04
US7452886B2 (en) 2008-11-18
NO20041180L (no) 2004-03-19
DE60211530D1 (de) 2006-06-22
KR20040029123A (ko) 2004-04-03
JP2005502683A (ja) 2005-01-27
PT1423391E (pt) 2006-09-29
CA2458684A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
GB0121033D0 (en) Organic compounds
GB0220187D0 (en) Organic compounds
GB0304640D0 (en) Organic compounds
PL367821A1 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
PL372316A1 (en) Glutaminyl based dpiv inhibitors
GB0223040D0 (en) Therapeutic compounds
GB0112348D0 (en) Compounds
JO2473B1 (en) Pyrazoles as inhibitors of tumor necrosis factor
ATE357453T1 (de) Comt-inhibitoren
MXPA05007607A (es) Inhibidores amida y ester de la metaloproteinasa de matriz.
IN2005KO00312A (enExample)
SI1606288T1 (sl) Derivati benzensulfonamida, postopek za njihovo pripravo in njihova uporaba za zdravljenje bolečine
EE200300394A (et) GlyT-1 inhibiitorid
ECSP044989A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades
AU2002254907A1 (en) Diamides which inhibit tryptase and factor xa activity

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)